

1 Effectiveness of Autumn 2023 COVID-19 vaccination and residual  
2 protection of prior doses against hospitalisation in England, estimated  
3 using a test-negative case-control study.

4 Freja Cordelia Møller Kirsebom PhD\*<sup>1</sup>, Julia Stowe PhD<sup>1</sup>, Jamie Lopez Bernal PhD\*<sup>1,2,3</sup>, Alex Allen  
5 BMBCh<sup>1</sup>, Nick Andrews PhD<sup>1,2</sup>

6 \*Corresponding author: [Freja.kirsebom@ukhsa.gov.uk](mailto:Freja.kirsebom@ukhsa.gov.uk)

7

- 8 1. UK Health Security Agency, London, United Kingdom  
9 2. NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of  
10 Hygiene and Tropical Medicine, London, United Kingdom  
11 3. NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London,  
12 United Kingdom

13 Word Count: 3938

## 14 Abstract

### 15 Introduction

16 The last COVID-19 vaccine offered to all adults in England became available from November 2021.  
17 The most recent booster programme commenced in September 2023. Bivalent BA.4-5 or  
18 monovalent XBB.1.5 boosters were given. During the study period, the JN.1 variant became  
19 dominant in England.

### 20 Methods

21 Vaccine effectiveness against hospitalisation was estimated throughout using the test-negative case-  
22 control study design where positive PCR tests from hospitalised individuals are cases and  
23 comparable negative PCR tests are controls. Multivariable logistic regression was used to assess  
24 vaccine effectiveness against hospitalisation with the test result as the outcome, vaccination status  
25 as the primary exposure variable of interest and confounder adjustment.

### 26 Results

27 There was no evidence of residual protection for boosters given as part of previous campaigns.  
28 There were 28,916 eligible tests included to estimate the effectiveness of the autumn 2023 boosters  
29 in those aged 65 years and older. VE peaked at 50.6% (95% CI: 44.2-56.3%) after 2-4 weeks, followed  
30 by waning to 13.6% (95% CI: -11.7-33.2%). Estimates were generally higher for the XBB.1.5 booster  
31 than the BA.4-5 booster, but this difference was not statistically significant. Point estimates were  
32 highest against XBB sub-lineages. Effectiveness was lower against both JN.1 and EG.5.1 variants with  
33 confidence intervals non-overlapping with the effectiveness of the XBB sub-lineages at 2-4 weeks for  
34 EG.5.1 where VE was 44.5% (95% CI: 20.2- 61.4%) and at 5-9 weeks for JN.1 where VE was 26.4%  
35 (95%CI: -3.4-47.6%).

### 36 Conclusions

37 The recent monovalent XBB.1.5 and bivalent BA.4-5 boosters provided comparable and good  
38 protection against hospitalisation, however there was evidence of lower VE against hospitalisation of  
39 these boosters against JN.1.

### 40 Keywords

41 COVID-19, vaccine effectiveness, immunisation, observational study, test-negative case-control

## 42 Introduction

43 COVID-19 continues to cause waves of disease, largely driven by the emergence of novel variants  
44 and sub-lineages. Although vaccines continue to be updated to better target current variants, the  
45 effectiveness of booster vaccines against hospitalisation wanes (1-4). As such, many countries,  
46 including England, have opted for regular booster programmes to protect the most vulnerable from  
47 severe disease. In England, the XBB-related Omicron sub-lineages were dominant throughout most  
48 of 2023 (5). Sub-lineages of BA.2.86 first emerged in during summer 2023 with mutations facilitating  
49 high ACE2 binding affinity, although no substantial humoral immune escape or growth advantage  
50 was detected (6). JN.1 (BA.2.86.1.1) has an additional receptor binding domain mutation (L455S) and  
51 neutralisation studies have found JN.1 has significant enhanced immune escape as compared with  
52 BA.2.86 and XBB.1.5 (6). JN.1 was first detected in the United States (US) in September and by mid-  
53 December many countries, including England, were detecting an increase in sequenced cases (7). By  
54 late January, JN.1 was the dominant sub-lineage in England, accounting for 85% of sequenced cases  
55 (5).

56 As part of the COVID-19 vaccination programme in England, all adults in England were initially  
57 offered a primary course (consisting of two vaccine doses, or three doses in the immunosuppressed)  
58 and a booster dose, all based on the ancestral strain. The last vaccine offered to all adults in England  
59 became available from November 2021 (8). Since, there have been booster vaccination programmes  
60 each spring and autumn, targeting risk groups based primarily on age and clinical risk status (9-11).  
61 The vaccine type offered has varied as manufacturers have updated formulations to target emergent  
62 variants. Adults aged 50 to 64 years of age in England were last offered a booster during the autumn  
63 2022 programme, in which bivalent BA.1 mRNA vaccines were offered to all adults aged 50 years or  
64 over and clinically vulnerable people. As of March 2024, the most recent booster programme in  
65 England commenced in early September 2023 (12). Adults aged 65 years and older, residents of care  
66 homes for older adults, carers and those in a clinical group were offered either a bivalent BA.4-5  
67 booster (based on the ancestral strain and the BA.4-5 sub-lineages) or a monovalent XBB.1.5 booster  
68 (12). The roll-out of the BA.4-5 boosters started a few weeks prior to the roll-out of the XBB.1.5  
69 vaccine. Those aged 75 years and older were also eligible for boosters in spring 2022 and most  
70 recently in spring 2023 where the Sanofi/GSK AS03-adjuvanted monovalent beta variant vaccine and  
71 mRNA bivalent BA.4-5 vaccines were recommended (10).

72 The aim of this study was to use national level electronic healthcare datasets to estimate the vaccine  
73 effectiveness (VE) of the autumn 2023 bivalent BA.4-5 and monovalent XBB.1.5 boosters against  
74 hospitalisation. In addition, the residual protection of prior booster doses in the study period was  
75 assessed, as well as a variant specific analysis for the autumn 2023 boosters.

## 76 Materials and Methods

### 77 Study design

78 Vaccine effectiveness against hospitalisation was estimated throughout using the test-negative case-  
79 control (TNCC) study design, as previously described (1, 2, 13, 14) where positive PCR tests from  
80 hospitalised individuals are cases and negative PCR tests from hospitalised individuals are the  
81 controls. The study period was from 4<sup>th</sup> September 2023 to 21<sup>st</sup> January 2024, with data extracted on  
82 12<sup>th</sup> February 2024.

### 83 Data Sources

#### 84 COVID-19 Testing Data

85 Positive and negative PCR tests undertaken in hospital settings were identified from England's  
86 national COVID-19 testing data. Negative tests within 7 days of a previous negative test and within  
87 21 days of a subsequent positive test were excluded. All tests within 90 days of a previous positive  
88 test were excluded as these likely represent the same episode. The date of an individual's most  
89 recent prior positive test was also identified (PCR and self-reported lateral flow tests). Individuals  
90 contributed a maximum of one negative test, selected at random. Further details on the reasons for  
91 these exclusions are described previously (1, 14). In England, a subset of positive PCR tests undergo  
92 whole genome sequencing. Tests with sequencing information associated were included in the  
93 variant analysis. Where subsequent tests within 14 days included sequencing information, this was  
94 used to enrich variant status.

#### 95 Immunisation Information System (IIS)

96 The testing data were linked to the UKHSA IIS; a national vaccine register (formally the national  
97 immunisation management system (NIMS)) containing demographic information on the whole  
98 population of England registered with a GP, used to record all COVID-19 vaccination (15), using  
99 combinations of the unique individual NHS number, date of birth, surname, first name, and postcode  
100 using deterministic linkage. IIS was accessed for dates of vaccination and manufacturer, sex, date of  
101 birth, ethnicity, care home residency and residential address. Care home status is provided by the  
102 NHS and included those being resident in a care home as of March 2023. Postcodes were used to  
103 determine index of multiple deprivation (IMD) quintile (small area measures of relative deprivation  
104 based on postcode) and NHS region. Data on clinical risk group status (those identified as requiring  
105 an autumn 2023 booster by NHS CaaS (Cohorting as a Service) (16)) were also extracted. Booster  
106 doses were classified based on SNOMED coding and timing of vaccination. The following individuals  
107 were excluded from the main analyses; those who had received only one dose, those with less than  
108 12 weeks between the latest dose and the dose prior, those who received a vaccine by a  
109 manufacturer other than those offered. Additionally, those who were unvaccinated were excluded  
110 from all analyses of incremental VE where the comparator group was those who had received at  
111 least two prior doses.

#### 112 Hospital Admission Data

113 Secondary Uses Service (SUS) is the national electronic database of hospital admissions that provides  
114 timely updates of ICD-10 codes for completed hospital stays for all NHS hospitals in England (17).  
115 SUS is an administrative database used by commissioners and providers of NHS-funded care for  
116 purposes including healthcare planning and National Tariff reimbursement. Data on admissions are  
117 considered very complete although there is a lag of a few weeks. Therefore, the testing data were  
118 restricted to 3 weeks prior to the date the data were linked to SUS. Hospital inpatient admissions  
119 were linked using NHS number and date of birth. Length of stay was calculated as date of discharge  
120 minus the date of admission. Admissions were restricted to those with an ICD-10 coded acute

121 respiratory illness (ARI) discharge diagnosis in the primary diagnosis field (Supplementary Table 1),  
122 who were admitted for at least 2 days, where the date of test was 1 day before and up to 2 days  
123 after the admission (13).

#### 124 Covariates and adjustment

125 Vaccination status was the primary exposure variable of interest in all analyses. Additionally, all  
126 analyses included adjustment for week of test date, gender, age (five-year age bands), NHS region,  
127 IMD quintile, ethnicity and clinical risk group status (encoded as a categorial variable with a level for  
128 all conditions other than severe immunosuppression and a level for severe immunosuppression (as  
129 defined in the Green book (18)). Additionally, the analysis of long-term effectiveness in those aged  
130 18 to 49 years included adjustment for health and social care worker status. All analyses of those  
131 aged 50 years and older included adjustment for influenza vaccination status 2023/2024. All  
132 analyses of those aged 65 years and older included adjustment for care home resident status. Less  
133 than 8% of data were missing in any category. Missing ethnicity data were included as a separate  
134 category while missing data for gender and IMD were omitted (<3% were missing).

#### 135 Statistical methods

136 Multivariable logistic regression was used with the test result as the outcome, vaccination status as  
137 the primary exposure variable of interest and with confounder adjustment as described above. VE  
138 was calculated as 1- odds ratio and given as a percentage. To compare estimates, statistical  
139 significance was concluded where 95% confidence intervals (CIs) did not overlap.

140 The residual VE (after  $\geq 18$  months) of two or three doses of monovalent vaccine was estimated  
141 amongst those aged 18 to 49 (as of 31<sup>st</sup> August 2022 - not eligible for further boosters) who received  
142 no further doses, relative to those who were totally unvaccinated. For all other analyses except one  
143 sensitivity analysis, we estimated the incremental VE relative to those who had received at least two  
144 previous doses as we consider it most relevant to estimate the additional benefit of a booster in  
145 addition to the protection an individual has from past doses which have waned in effectiveness. The  
146 two previous doses also had to be at least 3 months prior to the test date. The residual incremental  
147 VE (after  $\geq 8$  months) of the bivalent BA.1 boosters given in autumn 2022 for those who got no  
148 further doses was estimated separately for those aged 50-63 years as of August 2023 (not eligible for  
149 an autumn 2023 dose) and those aged 65 years and older (eligible for an autumn 2023 dose). The  
150 residual incremental VE (in intervals 10-14, 15-19, 20-25,  $\geq 25$  weeks post vaccination) of the spring  
151 2023 boosters was estimated for those aged 75 years and older who had received no further doses  
152 by their test date. For this spring 2023 analysis the increment was within those who also received an  
153 autumn 2022 dose.

154 The incremental VE of the bivalent BA.4-5 and monovalent XBB.1.5 boosters given as part of the  
155 autumn 2023 programme was estimated for those aged 65 years and older whose last dose was  
156 administered at least 3 months prior at the following intervals since booster vaccination; 0-2 days, 3-  
157 8 days, 9-13 days, 2-4 weeks, 5-9 weeks, 10-14 weeks, and 15 or more weeks. Analyses were  
158 stratified separately by vaccine type and well as with vaccines combined. Within those cases with  
159 sequencing information available, VE was assessed by variant with manufacturers combined.

160 Additional analyses of the autumn 2023 boosters were conducted restricting to those aged 75 years  
161 and older, and in those aged 18 to 64 years who were in a clinical risk group. Sensitivity analyses  
162 were undertaken to assess the effect of comparing those boosted to those not boosted irrespective  
163 of prior vaccination, including adjustment for prior infection, excluding adjustment for influenza  
164 vaccine status this season (2023/2024), estimating VE against all hospitalisations, regardless of ICD-  
165 10 coding.

## 166 Results

167 During the study period there were 3,428 eligible tests included in the analysis to estimate residual  
168 monovalent VE in those aged 18–49, 3,621 eligible tests included to estimate the residual autumn  
169 2022 booster VE in 50-63 year olds, 8,790 eligible tests included to estimate the residual autumn  
170 2022 booster VE in those aged 65 years and older, 7,123 eligible tests included to estimate the  
171 residual spring 2023 VE in those aged 75 years and older, and 28,916 eligible tests included to  
172 estimate the VE of the autumn 2023 boosters in those aged 65 years and older. Supplementary  
173 Tables 1-5 give details of the numbers of cases (positive tests) and controls (negative tests) by  
174 demographic factors and Supplementary Figure 1 details the numbers of cases and controls by  
175 calendar week.

### 176 Residual protection of prior doses against hospitalisation.

177 Residual incremental VE of prior doses is shown in Table 1. We found no evidence of residual VE for  
178 the monovalent boosters or the 2022 bivalent autumn boosters. The spring booster given in 2023 to  
179 those aged 75 years and over showed effectiveness waning from 30.8% (95% CI: 8.2 to 47.9%) at 10-  
180 14 weeks to no incremental protection after 20 or more weeks.

### 181 Effectiveness of the autumn 2023 XBB.1.5 and BA.4-5 boosters against hospitalisation.

182 The autumn 2023 booster VE peaked at 50.6% (95% CI: 44.2 to 56.3%) 2-4 weeks after vaccination,  
183 followed by waning to 13.6% (95% CI: -11.7 to 33.2%) by 15+ weeks (Table 2). The apparent VE  
184 within 0-2 days of 65.9% (95% CI: 52.5 to 75.5%) is not a true protective effect and likely a bias due  
185 to deferral of vaccination in individuals who were already aware of their COVID-19 positive status  
186 from home lateral flow testing and/or a healthy vaccinee effect in which those with early symptoms  
187 of COVID-19 were more unwell than controls and were less likely to be vaccinated. This bias should  
188 be transient as indicated by apparent VE reducing at 3-8 days to 31.0% (95% CI: 17.1 to 42.5%).

189 VE point estimates were generally higher for the XBB.1.5 booster as compared to the BA.4-5  
190 booster, but confidence intervals overlapped at all time intervals investigated and this difference  
191 was therefore not statistically significant (Table 2). There were insufficient data to estimate VE at 15  
192 or more weeks post vaccination for the XBB.1.5 booster, but VE after this period was 16.9% (95%CI: -  
193 8.3 to 36.2%) for the BA.4-5 booster (Table 2).

194 When the analysis was stratified to just those aged 75 years and older, VE estimates remained  
195 similar (Supplementary Table 6). We investigated VE amongst adults aged 18 to 64 years who were  
196 in a clinical risk group and therefore also eligible for vaccination during the autumn 2023 programme  
197 (Supplementary Table 6, full descriptive characteristics in Supplementary Table 7). As the numbers of  
198 cases and controls were small, we could not stratify by vaccine type. Nonetheless, protection against  
199 hospitalisation was also observed in this population; VE was 41.5% (95%CI: 16.8 to 58.9%) after 2-4  
200 weeks post vaccination.

201 Sensitivity analyses are presented in Supplementary Table 6. We conducted a sensitivity analysis  
202 where we included adjustment for past infection; this did not impact our VE estimates. We also  
203 removed the adjustment for influenza vaccination status this season (2023/2024) and this also did  
204 not alter the VE estimates. In a further sensitivity analysis, we estimated VE against all hospital  
205 admissions, regardless of the ICD-10 coding in the primary diagnosis field; this also had no significant  
206 impact on VE estimates. Finally, we assessed VE when comparing those boosted to those not  
207 boosted (irrespective of past vaccination) and found VE was also similar (Supplementary Table 6).

208 Effectiveness of the autumn 2023 booster against hospitalisation with JN.1, EG.5.1 and XBB  
209 sub-lineages  
210 For cases where sequencing was done the effectiveness of the autumn 2023 boosters against  
211 hospitalisation amongst those aged 65 years and older was estimated stratified by the Omicron sub-  
212 lineages prevalent during the study period; XBB sub-lineages, EG.5.1 and JN.1. The numbers of  
213 variant cases by calendar week in the study period are shown in Supplementary Figure 2.

214 Vaccine effectiveness point estimates were highest against XBB sub-lineages with VE as high as  
215 74.0% (95%CI: 62.4 to 82.1%) at 2-4 weeks and 68.2% (95%CI: 52.9 to 78.5%) at 5-9 weeks (Table 3).  
216 VE was lower against both JN.1 and EG.5.1 with confidence intervals non-overlapping with the VE of  
217 the XBB sub-lineages at 2-4 weeks for EG.5.1 where VE was 44.5% (95% CI: 20.2 to 61.4%) and at 5-9  
218 weeks for JN.1 where VE was 26.4% (95%CI: -3.4 to 47.6%).

219 After 10 or more weeks, the protection against hospitalisation was 22.5% (95%CI: -4.4 to 42.5%),  
220 21.6% (95%CI: -43.0 to 57.0%) and 55.1% (95% CI: 23.1 to 73.8%) for JN.1, EG.5.1 and XBB sub-  
221 lineages, respectively (Table 3). It should be noted that in this longer period post vaccination  
222 numbers are small for the JN.1 and EG.5.1 analyses, and the mean time since vaccination within this  
223 interval will be shorter than that for JN.1 (the distribution of time since vaccination by variant is  
224 shown in Supplementary Figure 3).

## 225 Conclusions

226 We here used a TNCC study design to estimate protection from the COVID-19 vaccines against  
227 hospitalisation amongst all adults in England, depending on which vaccine individuals were last  
228 eligible for. Overall, we find that effectiveness of doses given prior to the most recent autumn 2023  
229 booster now provide minimal protection against hospitalisation. The most recent XBB.1.5 and BA.4-5  
230 boosters given as part of the autumn 2023 programme provided good protection amongst those  
231 aged 65 years and older. Protection peaked at around 40-50% against hospitalisation in addition to  
232 the waned immunity from prior doses. There was evidence of waning of protection of these  
233 boosters, but this was partially confounded by the emergence of the JN.1 variant in England towards  
234 the end of the study period for which we found evidence of reduced VE.

235 Adults aged 18 to 49 years in England were last offered a two-dose primary course and booster  
236 (third dose) from November 2021. The current effectiveness of these doses after at least 18 months  
237 was minimal; there was no longer any significant protection against hospitalisation as compared to  
238 their unvaccinated peers. Previously, we observed high VE against hospitalisation for these vaccines,  
239 but low VE was observed against mild disease (13, 14, 19) and infection (20). Since, there have been  
240 multiple waves of infections and therefore many individuals' (both vaccinated and unvaccinated)  
241 most recent immunising event will be an infection. The reduced protection we observed is therefore  
242 partly attributable to waning but also likely reflective of the very high level of immunity in both  
243 unvaccinated and vaccinated individuals from waves of prior infections over the last two years.  
244 COVID-19 hospitalisation rates remain very low for younger adults and England's national  
245 surveillance data do not indicate that this population is at risk of severe disease (5).

246 The incremental VE of the BA.1 bivalent booster offered in the autumn of 2022 and of the spring  
247 booster administered in 2023 was also found to be minimal after 8 months and after 5 months,  
248 respectively, indicating that these doses are no longer providing additional protection against  
249 hospitalisation as compared to those who had received at least two doses but had not received a  
250 booster as part of that programme. This is also likely also due to a combination of waning and recent  
251 infections increasing the immunity in the comparator group to a comparable level to those  
252 vaccinated. Although waves of COVID-19 continue to occur, the magnitude of hospitalisations has  
253 decreased with each wave (21), indicating that those waned immunity are not necessarily at  
254 increased risk of severe disease. Policy decisions around the timing of vaccination must consider the  
255 short-lived duration of protection to maximise protection at the right time for those at higher risk of  
256 severe disease. This may be challenging as COVID-19 waves do not follow a seasonal pattern and  
257 occur throughout the year due to the emergence of novel sub-lineages, the timing of which is  
258 difficult to predict.

259 The effectiveness of the most recent boosters, the monovalent XBB.1.5 and bivalent BA.4-5 vaccines,  
260 amongst those aged 65 years was comparable to the incremental protection we observed previously  
261 shortly after vaccination with the bivalent BA.1 boosters (1) and with the Sanofi/GSK product (2). We  
262 did not observe a significant difference in protection by vaccine type. Early data using a cohort study  
263 design from Denmark found higher VE of the XBB.1.5 boosters - in their study vaccination was  
264 associated with a 76% reduced risk of COVID-19 hospitalisation (22). However, the average follow-up  
265 time post vaccination was just 9.9 days. VE results from TNCC studies from the US and Canada were  
266 broadly similar to our study and found VE of the XBB.1.5 boosters to be 46% against symptomatic  
267 infection (23) and 47% against medically attended outpatient COVID-19 (24). In a stratified analysis  
268 we found VE of was similar for those aged 75 years and older who are considered at higher risk of  
269 severe disease. We also found moderate protection in adults aged 18-64 years who were in a clinical  
270 risk group and therefore also eligible for vaccination. Point estimates for younger adults in a clinical



271 risk group were lower than the VE estimates for adults aged 65 years and older, although numbers  
272 of cases and controls included in the analysis were smaller and therefore the precision around the  
273 estimates was also lower. We found VE was similar if we simply compared those boosted to those  
274 not boosted, rather than restricting to the analysis being within those with at least 2 prior doses.  
275 This is not surprising given the minimal residual VE of prior doses seen.

276 Since freely available community COVID-19 testing ended in April 2021 in England, most infections  
277 are now unreported. In sensitivity analyses we found that there was no difference between the VE  
278 estimates when we included adjustment for the likely variant of a person's most recent prior  
279 infection in the model. This is in agreement with previous studies where we have also not found a  
280 difference (1, 2). Influenza vaccination status this season (2023/2024) was adjusted for in the  
281 primary analysis. An assumption of the TNCC design is that the risk of being a control (a non-COVID-  
282 19 respiratory hospitalisation) is independent of vaccination status. This may not be the case when  
283 influenza and COVID-19 are co-circulating as those receiving a COVID-19 vaccine are also more likely  
284 to receive an influenza vaccine (25). One option, if all samples were tested for influenza would be to  
285 remove these controls, but as this was not done we instead adjusted for influenza vaccination status  
286 despite a level of collinearity with COVID-19 vaccination. Reassuringly, we did not find that influenza  
287 vaccination had a protective effect against COVID-19 hospitalisation and in sensitivity analyses we  
288 did not find that removing the adjustment for influenza vaccination status had an effect on the VE  
289 estimates.

290 There was evidence of waning after 10 weeks post vaccination for both the XBB.1.5 and BA.4-5  
291 boosters. This is also in line with when we have observed waning for previous boosters (1, 2) but this  
292 was partially confounded by the emergence of JN.1 during the study period. A study of vaccine  
293 effectiveness (VE) against symptomatic disease from the US found no significant difference in VE  
294 between likely JN.1 and non-JN.1 cases (identified by S-gene target status) (23) however a study  
295 from Denmark found that JN.1 cases had higher odds of being vaccinated than non-BA.2.86 cases –  
296 suggesting lower real-world effectiveness (26). In agreement with the Danish study, we also found  
297 evidence of reduced effectiveness in the period 5-9 weeks post-vaccination. This difference was  
298 significant when comparing VE against JN.1 and XBB-related sub-lineages but not significant when  
299 comparing VE against JN.1 and EG.5.1, possibly due to the XBB.1.5 vaccine being better matched to  
300 XBB-related sub-lineages. While England saw a wave of cases driven by the emergence of JN.1,  
301 which peaked around week 01 of 2024, this has since declined and was similar or smaller in  
302 magnitude to previous waves (5), suggesting that despite lower VE, population-wide immunity (from  
303 vaccines or natural infections) has suppressed the JN.1 wave in England.

304 A strength of this study is the use of national-level electronic healthcare datasets to estimate VE  
305 against hospitalisation for the population of England. To our knowledge, this is the only recent study  
306 which has investigated the long-term duration of protection in the whole population, therefore  
307 giving insight into the status of the population as a whole and not just those offered the most recent  
308 booster. A key strength is also the use of the TNCC study design which helps to address unmeasured  
309 confounders related to differences in health-seeking behaviours, health care access and infectious-  
310 disease exposure between vaccinated and unvaccinated people. Nonetheless our study has several  
311 limitations; even with the use of national-level datasets, COVID-19 testing and whole genome  
312 sequencing has been scaled down which limits the speed at which we able to estimate VE in  
313 response to emergent variants, and the precision around the estimates. It is therefore more  
314 challenging to tease apart smaller differences in VE between vaccine types and co-circulating  
315 variants. Additionally, since this is an observational study, there may have been unmeasured or  
316 residual confounding which we were not able to adjust for.

317 Overall, we here find evidence that those vaccinated during earlier campaigns in England are no  
318 longer better protected than their unvaccinated counterparts. The recent monovalent XBB.1.5 and  
319 bivalent BA.4-5 boosters provided comparable and good protection against hospitalisation amongst  
320 those aged 65 years and older, however there was evidence of lower VE against hospitalisation of  
321 these boosters against JN.1.

322 Tables

323 Table 1. Long-term duration of protection of doses given prior to the autumn 2023 vaccination  
324 programme.

Age (years)	Vaccine	Waned period	Controls	Cases	VE (95% CI)
18-49	Unvaccinated	-	777	129	Baseline
	2 doses of monovalent vaccine	18+ months	826	134	1.3 (-31.2 to 25.7)
	3 doses of monovalent vaccine	18+ months	1378	184	9.6 (-18.4 to 31.1)
50-63	No bivalent BA.1 booster*	-	1678	350	Baseline
	Bivalent BA.1 booster autumn 2022*	8+ months	1275	318	-3.7 (-24.8 to 13.7)
65+	No bivalent BA.1 booster*	-	2972	1170	Baseline
	Bivalent BA.1 booster autumn 2022*	8+ months	3299	1349	8.6 (-0.9 to 17.3)
75+	No spring booster**	-	1,727	782	Baseline
	Spring booster 2023**	10-14 weeks	205	85	30.8 (8.2 to 47.9)
		15-19 weeks	883	446	14.4 (-0.2 to 26.9)
		20-24 weeks	1211	680	-3.2 (-18.5 to 10.1)
		25+ weeks	813	291	-3.1 (-22.7 to 13.4)

325 \* In addition to at least two prior monovalent doses, waned for at least 3 months

326 \*\* In addition to at least two prior monovalent doses where the last dose was a BA.1 bivalent dose given as  
327 part of the autumn 2022 programme, waned for at least 3 months

328 Table 2. Vaccine effectiveness of the monovalent XBB.1.5 vaccine and the bivalent BA.4-5 vaccine  
329 against hospitalisation amongst those aged 65 years and older in England.

Booster vaccine*	Time since vaccination	Controls	Cases	OR (95% CI)	VE (95% CI)
Primary analysis; vaccine products combined					
None	-	10,227	4351	Baseline	Baseline
Autumn 2023 booster	0-2 days	245	44	0.34 (0.25-0.47)	65.9 (52.5 to 75.5)
	3-8 days	517	182	0.69 (0.57-0.83)	31.0 (17.1 to 42.5)
	9-13 days	496	136	0.59 (0.48-0.72)	41.2 (28.0 to 52.1)
	2-4 weeks	2464	460	0.49 (0.44-0.56)	50.6 (44.2 to 56.3)
	5-9 weeks	4206	700	0.54 (0.49-0.61)	45.7 (39.4 to 51.3)
	10-14 weeks	3581	791	0.64 (0.57-0.71)	36.5 (28.8 to 43.4)
	15+ weeks	420	96	0.86 (0.67-1.12)	13.6 (-11.7 to 33.2)
Stratified by vaccine product type					
None	-	10,227	4351	Baseline	Baseline
XBB.1.5 monovalent	0-2 days	124	26	0.46 (0.30-0.71)	54.1 (29.3 to 70.2)
	3-8 days	294	90	0.70 (0.54-0.90)	30.2 (10.2 to 45.7)
	9-13 days	290	72	0.63 (0.48-0.82)	37.4 (17.8 to 52.3)
	2-4 weeks	1464	214	0.45 (0.38-0.53)	54.8 (46.8 to 61.6)
	5-9 weeks	2292	393	0.52 (0.45-0.59)	48.3 (41.0 to 54.7)
	10-14 weeks	1445	296	0.58 (0.49-0.68)	42.2 (32.3 to 50.6)
	15+ weeks	27	7	n too small	n too small
BA.4-5 bivalent	0-2 days	121	18	0.25 (0.15-0.41)	75.1 (58.8 to 85.0)
	3-8 days	223	92	0.69 (0.54-0.90)	30.2 (10.2 to 45.7)
	9-13 days	206	64	0.56 (0.42-0.75)	44.1 (25.1 to 58.3)
	2-4 weeks	1000	246	0.55 (0.47-0.64)	45.0 (35.5 to 53.2)
	5-9 weeks	1914	307	0.58 (0.50-0.67)	42.4 (33.4 to 50.2)
	10-14 weeks	2136	495	0.66 (0.58-0.75)	34.3 (25.2 to 42.3)
	15+ weeks	393	89	0.83 (0.64-1.08)	16.9 (-8.3 to 36.2)

330 \* In addition to at least two prior doses, waned for at least 3 months

331 Table 3. Vaccine effectiveness of the autumn 2023 booster vaccines against hospitalisation with  
332 JN.1, EG.5.1 and XBB sub-lineages, amongst those aged 65 years and older in England.

Booster vaccine	Time since vaccination	Controls	Cases	OR (95% CI)	VE (95% CI)
JN.1					
None	-	10,227	118	Baseline	Baseline
Autumn 2023 booster*	2-4 weeks	2464	12	0.63 (0.34-1.19)	36.6 (-19.5 to 66.4)
	5-9 weeks	4206	73	0.74 (0.52-1.03)	26.4 (-3.4 to 47.6)
	10+ weeks	4001	163	0.77 (0.58-1.04)	22.5 (-4.4 to 42.5)
EG.5.1					
None	-	10,227	357	Baseline	Baseline
Autumn 2023 booster*	2-4 weeks	2464	48	0.55 (0.39-0.80)	44.5 (20.2 to 61.4)
	5-9 weeks	4206	40	0.57 (0.37-0.86)	43.2 (13.7 to 62.7)
	10+ weeks	4001	21	0.78 (0.43-1.43)	21.6 (-43.0 to 57.0)
XBB sub-lineages					
None	-	10,227	649	Baseline	Baseline
Autumn 2023 booster*	2-4 weeks	2464	37	0.26 (0.18-0.38)	74.0 (62.4 to 82.1)
	5-9 weeks	4206	37	0.32 (0.22-0.47)	68.2 (52.9 to 78.5)
	10+ weeks	4001	22	0.45 (0.26-0.77)	55.1 (23.1 to 73.8)

\*Of the bivalent BA.4-5 booster or the monovalent XBB.1.5 booster

### 334 Authors' Contributions

335 NA, FCMK and JLB conceptualised the study. FCMK, JS and NA developed the methodology. FCMK  
336 curated the data. FCMK accessed and verified the data. FCMK conducted the formal analysis,  
337 supported by NA. FCMK wrote the original draft of the manuscript. JLB and AA provided supervision.  
338 All co-authors reviewed the manuscript and were responsible for the decision to submit the  
339 manuscript.

### 340 Data Sharing Statement

341 This work is carried out under Regulation 3 of The Health Service (Control of Patient Information;  
342 Secretary of State for Health, 2002) using patient identification information without individual  
343 patient consent as part of the UKHSA legal requirement for public health surveillance and  
344 monitoring of vaccines. As such, authors cannot make the underlying dataset publicly available for  
345 ethical and legal reasons. However, all the data used for this analysis is included as aggregated data  
346 in the manuscript tables and appendix. Applications for relevant anonymised data should be  
347 submitted to the UKHSA Office for Data Release at  
348 <https://www.gov.uk/government/publications/accessing-ukhsa-protected-data>.

### 349 Declaration of Interests

350 The Immunisation Department provides vaccine manufacturers (including Pfizer) with post-  
351 marketing surveillance reports about pneumococcal and meningococcal disease which the  
352 companies are required to submit to the UK Licensing authority in compliance with their Risk  
353 Management Strategy. A cost recovery charge is made for these reports.

### 354 Ethics Committee Approval

355 The study protocol was subject to an internal review by the UK Health Security Agency Research  
356 Ethics and Governance Group and was found to be fully compliant with all regulatory requirements.  
357 As no regulatory issues were identified, and ethical review is not a requirement for this type of work,  
358 it was decided that a full ethical review would not be necessary. UKHSA has legal permission,  
359 provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002, to  
360 process patient confidential information for national surveillance of communicable diseases and as  
361 such, individual patient consent is not required to access records.

### 362 Role of funding source

363 No external funding.

## 364 References

365

366 1. Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Lopez Bernal J. Duration of  
367 protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1  
368 boosters against COVID-19 hospitalisation in England: a test-negative case-control  
369 study. *The Lancet Infectious Diseases*. 2023;0(0).

370 2. Kirsebom FCM, Andrews N, Stowe J, Dabrera G, Ramsay M, Bernal JL.  
371 Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech  
372 (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation  
373 amongst adults aged 75 years and older in England, estimated using a test-negative  
374 case control study design. *medRxiv*. 2023:2023.09.28.23296290.

375 3. Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, et al. Early  
376 Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing  
377 Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-  
378 Related Sublineages Among Immunocompetent Adults - Increasing Community Access  
379 to Testing Program, United States, December 2022-January 2023. *MMWR Morbidity  
380 and mortality weekly report*. 2023;72(5):119-24.

381 4. Tenforde Mw Fau - Weber ZA, Weber Za Fau - Natarajan K, Natarajan K Fau -  
382 Klein NP, Klein Np Fau - Kharbanda AB, Kharbanda Ab Fau - Stenehjem E, Stenehjem E  
383 Fau - Embi PJ, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in  
384 Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters  
385 and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States,  
386 September-November 2022. *MMWR Morbidity and mortality weekly report*.  
387 2022(1545-861X (Electronic)).

388 5. UK Health Security Agency. National Influenza and COVID-19 surveillance  
389 report: Week 9 report (up to week 8 data) 2024 [Available from:  
390 [https://assets.publishing.service.gov.uk/media/65e07c292f2b3b001c7cd778/Weekly-  
391 flu-and-COVID-19-surveillance-report-week-9.pdf](https://assets.publishing.service.gov.uk/media/65e07c292f2b3b001c7cd778/Weekly-flu-and-COVID-19-surveillance-report-week-9.pdf)].

392 6. Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, et al. Fast evolution of SARS-CoV-  
393 2 BA.2.86 to JN.1 under heavy immune pressure. *The Lancet Infectious diseases*.  
394 2024;24(2):e70-e2.

395 7. World Health Organisation. Initial risk evaluation of JN.1, 19 December 2023  
396 2023 [Available from: [https://www.who.int/docs/default-  
397 source/coronaviruse/18122023\\_jn.1\\_ire\\_clean.pdf?sfvrsn=6103754a\\_3](https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3)].

398 8. Department of Health & Social Care. Joint Committee on Vaccination and  
399 Immunisation: advice on priority groups for COVID-19 vaccination, 30 December 2020  
400 [Available from: [www.gov.uk/government/publications/priority-groups-for-  
401 coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020/joint-  
402 committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-  
403 vaccination-30-december-2020](http://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020)].

404 9. Joint Committee on Vaccination and Immunisation. Joint Committee on  
405 Vaccination and Immunisation (JCVI) statement on COVID-19 vaccinations in 2022: 21  
406 February 2022. 2022.

- 407 10. Joint Committee on Vaccination and Immunisation. JCVI statement on spring  
408 2023 COVID-19 vaccinations, 22 February 2023 2023 [Available from:  
409 [https://www.gov.uk/government/publications/spring-2023-covid-19-vaccination-](https://www.gov.uk/government/publications/spring-2023-covid-19-vaccination-programme-jcvi-advice-22-february-2023/jcvi-statement-on-spring-2023-covid-19-vaccinations-22-february-2023)  
410 [programme-jcvi-advice-22-february-2023/jcvi-statement-on-spring-2023-covid-19-](https://www.gov.uk/government/publications/spring-2023-covid-19-vaccination-programme-jcvi-advice-22-february-2023/jcvi-statement-on-spring-2023-covid-19-vaccinations-22-february-2023)  
411 [vaccinations-22-february-2023](https://www.gov.uk/government/publications/spring-2023-covid-19-vaccination-programme-jcvi-advice-22-february-2023/jcvi-statement-on-spring-2023-covid-19-vaccinations-22-february-2023).  
412 11. Joint Committee on Vaccination and Immunisation. JCVI updated statement on  
413 the COVID-19 vaccination programme for autumn 2022 2022 [Available from:  
414 [https://www.gov.uk/government/publications/jcvi-updated-statement-on-the-covid-](https://www.gov.uk/government/publications/jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022)  
415 [19-vaccination-programme-for-autumn-2022](https://www.gov.uk/government/publications/jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022).  
416 12. Joint Committee on Vaccination and Immunisation. JCVI statement on the  
417 COVID-19 vaccination programme for autumn 2023 - update 7 July 2023 2024  
418 [Available from: [https://www.gov.uk/government/publications/covid-19-autumn-](https://www.gov.uk/government/publications/covid-19-autumn-2023-vaccination-programme-jcvi-update-7-july-2023/jcvi-statement-on-the-covid-19-vaccination-programme-for-autumn-2023-update-7-july-2023)  
419 [2023-vaccination-programme-jcvi-update-7-july-2023/jcvi-statement-on-the-covid-](https://www.gov.uk/government/publications/covid-19-autumn-2023-vaccination-programme-jcvi-update-7-july-2023/jcvi-statement-on-the-covid-19-vaccination-programme-for-autumn-2023-update-7-july-2023)  
420 [19-vaccination-programme-for-autumn-2023-update-7-july-2023](https://www.gov.uk/government/publications/covid-19-autumn-2023-vaccination-programme-jcvi-update-7-july-2023/jcvi-statement-on-the-covid-19-vaccination-programme-for-autumn-2023-update-7-july-2023).  
421 13. Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-  
422 19 vaccines against Omicron and Delta hospitalisation, a test negative case-control  
423 study. *Nature communications*. 2022;13(1):5736.  
424 14. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-  
425 19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *New England*  
426 *Journal of Medicine*. 2022.  
427 15. Tessier E, Edelstein M, Tsang C, Kirsebom F, Gower C, Campbell CNJ, et al.  
428 Monitoring the COVID-19 immunisation programme through a national immunisation  
429 Management system – England’s experience. *International Journal of Medical*  
430 *Informatics*. 2023;170:104974.  
431 16. NHS Digital. Cohorting as a Service (CaaS) 2022 [Available from:  
432 <https://digital.nhs.uk/services/cohorting-as-a-service-caas>.  
433 17. NHS Digital. Secondary Uses Service (SUS) 2022 [Available from:  
434 <https://digital.nhs.uk/services/secondary-uses-service-sus>.  
435 18. UK Health Security Agency. COVID-19: the green book, chapter 14a.  
436 Immunisation against infectious diseases: UK Health Security Agency,; 2020.  
437 19. Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, et al.  
438 COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. *The*  
439 *Lancet Infectious Diseases*. 2022;22(7):931-3.  
440 20. Kirwan PD, Hall VJ, Foulkes S, Otter AD, Munro K, Sparkes D, et al. Effect of  
441 second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN  
442 healthcare worker cohort. *Lancet Reg Health Eur*. 2024;36:100809.  
443 21. UK Health Security Agency. UK Coronavirus Dashboard; Healthcare in England  
444 2024 [Available from:  
445 [https://coronavirus.data.gov.uk/details/healthcare?areaType=nation&areaName=Engl](https://coronavirus.data.gov.uk/details/healthcare?areaType=nation&areaName=England)  
446 [and](https://coronavirus.data.gov.uk/details/healthcare?areaType=nation&areaName=England).  
447 22. Hansen CH, Moustsen-Helms IR, Rasmussen M, Soborg B, Ullum H, Valentiner-  
448 Branth P. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against



- 449 hospitalisation in Denmark: a national cohort study. *The Lancet Infectious diseases*.  
450 2024;24(2):e73-e4.
- 451 23. Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, et al. Early  
452 Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine  
453 Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-  
454 Circulating Omicron Variants Among Immunocompetent Adults - Increasing  
455 Community Access to Testing Program, United States, September 2023-January 2024.  
456 *MMWR Morbidity and mortality weekly report*. 2024;73(4):77-83.
- 457 24. Skowronski DM, Zhan Y, Kaweski SE, Sabaiduc S, Khalid A, Olsha R, et al.  
458 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates  
459 from the Canadian Sentinel Practitioner Surveillance Network (SPSN). *Euro*  
460 *surveillance : bulletin Europeen sur les maladies transmissibles = European*  
461 *communicable disease bulletin*. 2024;29(7).
- 462 25. Doll MK, Pettigrew SM, Ma J, Verma A. Effects of Confounding Bias in  
463 Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-  
464 Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors.  
465 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of*  
466 *America*. 2022;75(1):e564-e71.
- 467 26. Moustsen-Helms I, Bager P, Larsen T, Trier Møller F, Vestergaard L,  
468 Christiansen L, et al. Relative Vaccine Protection, Disease Severity and Symptoms  
469 Associated with Infection with SARS-CoV-2 Omicron Subvariant Ba.2.86 and  
470 Descendent Jn.1: A Danish Nationwide Register-Based Study. Preprint with SSRN.  
471 2024.
- 472